StockNews.AI
ZOM
StockNews.AI
194 days

Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis

1. Zomedica's TRUFORMA eACTH assay is now the only point-of-care solution for horses. 2. The assay's adoption since its September 2024 launch may boost ZOM's market position.

2m saved
Insight
Article

FAQ

Why Bullish?

The unique offering of the eACTH assay could increase demand and drive revenues. Historical product launches that filled market gaps often correlated with stock price increases.

How important is it?

The update on TRUFORMA's eACTH assay is vital for Zomedica's market strategy and competitive edge. Innovations in unique diagnostics can directly influence overall financial performance.

Why Long Term?

Sustained adoption and market share growth from the eACTH assay suggest lasting price impact. Past innovations in veterinary diagnostics led to prolonged positive market sentiment.

Related Companies

ZOM
Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic devices for equine and companion animals, today announced a groundbreaking update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform. Since it was launched in September of 2024, the TRUFORMA eACTH assay has been widely adopted as the only assay to measure eACTH in horses directly at the point-of-care.

Related News